IL15 and cancer: As highlighted in a recent Nature Outlook article on targeting NK cells in cancer [37], NK cell immunotherapies benefit from enhancing the IL-15 receptor signaling axis by adding IL-15 to therapeutics and/or targeting the negative regulators of IL-15 receptor signaling to increase the response of NK cells to the limited amount of endogenous IL-15 within the TME.